Drug Type Fc fusion protein |
Synonyms SL-086159 |
Target |
Action inhibitors, antagonists |
Mechanism CD86 inhibitors(Cluster of differentiation 86 inhibitors), NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 01 Nov 2019 |






